These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 22307626)

  • 1. Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases.
    Rick FG; Schally AV; Szalontay L; Block NL; Szepeshazi K; Nadji M; Zarandi M; Hohla F; Buchholz S; Seitz S
    Proc Natl Acad Sci U S A; 2012 Jan; 109(5):1655-60. PubMed ID: 22307626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer.
    Muñoz-Moreno L; Arenas MI; Schally AV; Fernández-Martínez AB; Zarka E; González-Santander M; Carmena MJ; Vacas E; Prieto JC; Bajo AM
    Int J Cancer; 2013 Feb; 132(4):755-65. PubMed ID: 22777643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia.
    Rick FG; Schally AV; Block NL; Nadji M; Szepeshazi K; Zarandi M; Vidaurre I; Perez R; Halmos G; Szalontay L
    Proc Natl Acad Sci U S A; 2011 Mar; 108(9):3755-60. PubMed ID: 21321192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway.
    Guo J; Schally AV; Zarandi M; Varga J; Leung PC
    Reprod Biol Endocrinol; 2010 May; 8():54. PubMed ID: 20509930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
    Heinrich E; Schally AV; Buchholz S; Rick FG; Halmos G; Mile M; Groot K; Hohla F; Zarandi M; Varga JL
    Prostate; 2008 Dec; 68(16):1763-72. PubMed ID: 18729085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer.
    Fahrenholtz CD; Rick FG; Garcia MI; Zarandi M; Cai RZ; Block NL; Schally AV; Burnstein KL
    Proc Natl Acad Sci U S A; 2014 Jan; 111(3):1084-9. PubMed ID: 24395797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer.
    Muñoz-Moreno L; Arenas MI; Carmena MJ; Schally AV; Sánchez-Chapado M; Prieto JC; Bajo AM
    Oncotarget; 2016 Aug; 7(32):52195-52206. PubMed ID: 27448980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.
    Seitz S; Rick FG; Schally AV; Treszl A; Hohla F; Szalontay L; Zarandi M; Ortmann O; Engel JB; Buchholz S
    Oncol Rep; 2013 Jul; 30(1):413-8. PubMed ID: 23624870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
    Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
    Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth hormone-releasing hormone antagonists abolish the transactivation of human epidermal growth factor receptors in advanced prostate cancer models.
    Muñoz-Moreno L; Arenas MI; Carmena MJ; Schally AV; Prieto JC; Bajo AM
    Invest New Drugs; 2014 Oct; 32(5):871-82. PubMed ID: 25000999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.
    Stangelberger A; Schally AV; Varga JL; Zarandi M; Szepeshazi K; Armatis P; Halmos G
    Clin Cancer Res; 2005 Jan; 11(1):49-57. PubMed ID: 15671527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer.
    Papadia A; Schally AV; Halmos G; Varga JL; Seitz S; Buchholz S; Rick F; Zarandi M; Bellyei S; Treszl A; Szalontay L; Lucci JA
    Horm Metab Res; 2011 Oct; 43(11):816-20. PubMed ID: 22009378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonists of growth hormone-releasing hormone inhibit the proliferation of human benign prostatic hyperplasia cells.
    Siejka A; Schally AV; Block NL; Barabutis N
    Prostate; 2010 Jul; 70(10):1087-93. PubMed ID: 20232355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antioxidant activity of growth hormone-releasing hormone antagonists in LNCaP human prostate cancer line.
    Barabutis N; Schally AV
    Proc Natl Acad Sci U S A; 2008 Dec; 105(51):20470-5. PubMed ID: 19075233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of GHRH antagonists on human glioblastomas and their mechanism of action.
    Pozsgai E; Schally AV; Zarandi M; Varga JL; Vidaurre I; Bellyei S
    Int J Cancer; 2010 Nov; 127(10):2313-22. PubMed ID: 20162575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers.
    Stangelberger A; Schally AV; Zarandi M; Heinrich E; Groot K; Havt A; Kanashiro CA; Varga JL; Halmos G
    Prostate; 2007 Sep; 67(12):1339-53. PubMed ID: 17624923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth hormone-releasing hormone antagonist induces apoptosis of human endometrial cancer cells through PKCδ-mediated activation of p53/p21.
    Wu HM; Schally AV; Cheng JC; Zarandi M; Varga J; Leung PC
    Cancer Lett; 2010 Dec; 298(1):16-25. PubMed ID: 20630651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells.
    Hohla F; Buchholz S; Schally AV; Seitz S; Rick FG; Szalontay L; Varga JL; Zarandi M; Halmos G; Vidaurre I; Krishan A; Kurtoglu M; Chandna S; Aigner E; Datz C
    Cell Cycle; 2009 Oct; 8(19):3149-56. PubMed ID: 19755849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Axis of GHRH and GHRH Receptor on Cell Viability and Apoptosis of the Placental Choriocarcinoma Cell Line.
    Liu AX; Zhang D; Zhu YM; Gao HJ; Jiang JY; Hu XL; Lv PP; Leung PC; Huang HF
    Curr Mol Med; 2016; 16(3):299-311. PubMed ID: 26917260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia.
    Rick FG; Schally AV; Block NL; Abi-Chaker A; Krishan A; Szalontay L
    Prostate; 2013 Jun; 73(8):873-83. PubMed ID: 23280565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.